CareDx在2025年第4季度错过了收入估计数,但收入增长强劲,业务有所改善,新的移植测试即将启动,领导力也发生了变化。 CareDx missed earnings estimates in Q4 2025 but saw strong revenue growth and operational improvements, with a new transplant test nearing launch and leadership changes.

CareDx报告,2025年的Q4收入为每股0.12美元,缺少估计数,虽然收入达到1.084亿美元,但比上一年增加25%,原因是测试量和产品采用率提高。 CareDx reported Q4 2025 earnings of $0.12 per share, missing estimates, though revenue hit $108.4 million, up 25% year-over-year, driven by higher testing volume and product adoption. 该公司预计2026年的收入为420万美元-444亿美元,其中750万美元来自有待改变的偿还费用。 The company expects 2026 revenue of $420M–$444M, with a $7.5M headwind from pending reimbursement changes. AlloHeme是移植拒绝试验,试验结果显著,预定在2027年启动。 AlloHeme, a transplant rejection test, showed strong results in trials and is set for a 2027 launch. CaredDx在年底的现金为201百万美元,没有债务,并完成了88百万美元的股票回购。 CareDx ended the year with $201M in cash, no debt, and completed $88M in share repurchases. 业务改进包括未偿日销售量下降至41天,拒绝报销率下降60%。 Operational improvements included a drop in days sales outstanding to 41 and a 60% decline in claim rejections. Nathan Smith将作为首席财务干事下台 由Keith Kennedy接管首席财务干事和首席财务干事的角色 Nathan Smith will step down as CFO, with Keith Kennedy taking over both CFO and COO roles.